Table 1.

Patient characteristics. Clinical and molecular features of patients overall, and stratified by TMB tertile: low (≤2.83 mutations/Mb), intermediate (2.84–4.85 mutations/Mb), and high (>4.85 mutations/Mb).

Total (n = 153)1st tertile (≤2.83; n = 60)2nd tertile (≤4.85; n = 42)3rd tertile (>4.85; n = 51)
Median age (range)64 (24–89)63 (34–88)66 (37–88)65 (25–89)
Sex
 Female101 (66%)42 (70%)30 (71%)28 (55%)
 Male52181223
Smoking status
 Never95 (62%)39 (65%)29 (69%)27 (53%)
 Ever (median pack years; range)58 (10; 0.5–74)21 (8; 3–74)13 (6; 3–24)24 (10; 0.5–46)
Year EGFR-TKI start
 2014 and earlier36 (24%)14 (23%)12 (29%)10 (20%)
 201554 (35%)24 (40%)17 (40%)14 (27%)
 2016–201763221327
Mutation
 L858R59 (39%)16 (27%)26 (62%)27 (53%)
 Exon 19 deletion94441624
TKI used
 Erlotinib141 (92%)55 (92%)38 (90%)48 (94%)
 Gefitinib11
 Afatanib11542
Oligoprogressiona15 (10%)3 (5%)9 (21%)3 (6%)
Median TMB (range)3.77 (0.43–17.92)2.04 (0.82–2.83)4.08 (3.06–4.72)6.60 (4.92–17.92)
  • aOligoprogression defined as radiographic/clinical progression of disease in ≤ 2 anatomic sites.